CAS OpenData Hub contains many interactive charts and tables. It is best viewed from laptop or desktop computer

COVID-19 Antibody Therapeutics Tracker

Legacy Manually Cleaned

The last update will be made in Aug. 1, 2021, after which, we will no longer maintain this dataset.

About this dataset

As the COVID-19 pandemic is the global healthcare crisis, scientists worldwide are collaborating to prevent or treat COVID-19. Antibody therapeutics hold enormous promise for treatment of COVID-19. Chinese Antibody Society is collaborating with our partner The Antibody Society to track the antibody-based therapeutics targeting COVID-19, to contribute our expertise to the globally joint efforts against the pandemic. In connection with the collaboration, The Antibody Society has published a “Coronavirus in the Crosshairs” series of articles addressing different aspects of therapeutics against COVID-19, and is continuous publishing new information and analysis. This tracker will be updated daily with the latest in developments for antibody therapeutics. If you notice an issue with this data or wish to submit an update, please contact us by email: Management@chineseantibody.org

References

This dataset has been described in the following mansucript. You are requested to cite the this article when you use the COVID-19 Antibody Therapeutics Tracker” from our paper:

Lifei Yang, Weihan Liu, Xin Yu, Meng Wu, Janice M Reichert, Mitchell Ho, COVID-19 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of COVID-19, Antibody Therapeutics

Stats at a Glance

217

Total Entries

62

Targets under investigation

133 programs targeting S protein

2

Antibodies approved for treatment

217 antibodies in phase 1 to 3

203

or more research groups and/or institutions

52 or more countries

Data Table

ID	Name	Target	Format	Status	Organization	Country	Derivation	Discovery platform
1	REGN-COV2 (REGN10933/Casirivimab + REGN10987/Imdevimab)	SARS-CoV-2 S protein	mAb	Phase 3	Regeneron/NIAID	USA	Humanized mouse or Human	unknown
2	Bamlanivimab (LY3819253, LY-CoV555)	SARS-CoV-2 S protein	mAb	Phase 3	AbCellera/Eli Lilly/NIH	Canada/USA	Human	Single B cell cloning
3	Sotrovimab (VIR-7831/GSK4182136)	SARS-CoV-2 S protein	mAb	Phase 3	Vir biotechnology/GSK	USA/UK	Human	Single B cell cloning
4	AZD7442 (AZD8895/Tixagevimab + AZD1061/Cilgavimab)	SARS-CoV-2 S protein	mAb	Phase 3	AstraZeneca/Vanderbilt University Medical Center/DARPA/BARDA	UK/USA	Human	Single B cell cloning
5	Regdanvimab (CT-P59)	SARS-CoV-2 S protein	mAb	Phase 3	Celltrion	South Korea	Human	unknown
6	TY027	SARS-CoV-2 S protein	mAb	Phase 3	Tychan	Singapore	unknown	unknown
7	BRII-196 + BRII-198	SARS-CoV-2 S protein	mAb	Phase 3	Brii Biosciences/NIAID	USA	unknown	unknown
8	DXP-593	SARS-CoV-2 S protein	mAb	Phase 2	Beigene/Singlomics Biopharmaceuticals/Peking University etc	China	Human	Single B cell cloning
9	Etesevimab (JS016, LY-CoV016, LY3832479)	SARS-CoV-2 S protein	mAb	Phase 2	Junshi Biosciences/Institute of Microbiology, Chinese Academy of Sciences/Eli Lilly	China/USA	Human	Single B cell cloning
10	DZIF-10c, BI 767551	SARS-CoV-2 S protein	mAb	Phase 2	University of Cologne/Boehringer Ingelheim	Germany	Human	Single B cell cloning
11	COVI-AMG (STI-2020)	SARS-CoV-2 S protein	mAb	Phase 2	Sorrento Therapeutics	USA	unknown	unknown
12	COR-101	SARS-CoV-2 S protein	mAb	Phase 2	YUMAB /CORAT therapeutics	Germany	Human	unknown
13	STI-1499/COVI-SHIELD	SARS-CoV-2 S protein	mAb	Phase 1	Sorrento/Mount Sinai Health System	USA	unknown	unknown
14	BRII-196	SARS-CoV-2 S protein	mAb	Phase 1	Brii Bio/TSB Therapeutics/Tsinghua University	China/USA	Human	Single B cell cloning
15	BRII-198	SARS-CoV-2 S protein	mAb	Phase 1	Brii Bio/TSB Therapeutics/Tsinghua University	China/USA	Human	Single B cell cloning
16	SCTA01	SARS-CoV-2 S protein	mAb	Phase 1	Sinocelltech Ltd/Chinese Academy of Sciences	China	unknown	unknown
17	MW33	SARS-CoV-2 S protein	mAb	Phase 1	Mabwell (Shanghai) Bioscience Co., Ltd.	China	unknown	unknown
18	HFB30132A	SARS-CoV-2 S protein	mAb	Phase 1	HiFiBiO Therapeutics	USA	unknown	unknown
19	ADM03820	SARS-CoV-2 S protein	mAb	Phase 1	Ology Bioservices	USA	unknown	unknown
20	47D11	SARS-CoV-2 S protein	mAb	Phase 1	Abbvie/Erasmus MC/Harbor BioMed/Utrecht University	Netherlands/China/USA	Humanized mouse	unknown
21	HLX70	SARS-CoV-2 S protein	mAb	Phase 1	Hengenix Biotech Inc	China	unknown	unknown
22	DXP-604	SARS-CoV-2 S protein	mAb	Phase 1	BeiGene/Singlomics	China	unknown	unknown
23	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Phase 1	Stanford University	USA	unknown	unknown
24	VIR-7832	SARS-CoV-2 S protein	mAb	Preclinical	Vir biotechnology/GSK	USA/UK	Human	Single B cell cloning
25	IDB003	SARS-CoV-2 S protein	mAb	Preclinical	Idbiologics Inc.	USA	unknown	unknown
26	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Adimab/Adagio Therapeutics	USA	unknown	unknown
27	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Shanghai henlius biotech/Sanyou Biopharmaceuticals/Shanghai ZJ Bio-Tech	China	Human	Phage display
28	Anti-SARS-CoV-2 mAb by non-viral gene delivery platform	SARS-CoV-2 S protein	mAb	Preclinical	Vir Biotechnology, Inc/ Generation Bio	USA	unknown	unknown
29	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Medicago/Laval University	Canada	unknown	unknown
30	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	AvantGen	USA	unknown	Yeast display
31	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Innovent Biologics	China	Human	unknown
32	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Ablexis, LLC, AlivaMab Discovery Services, LLC and Berkeley Lights, Inc	USA	unknown	unknown
33	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Ligand	USA	unknown	unknown
34	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Institut Pasteur	France	unknown	unknown
35	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	ThermoGenesis Holdings, Inc., ImmuneCyte/Zhejiang University School of Medicine/ East China Normal University	USA	Human	unknown
36	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Specifica	USA	unknown	unknown
37	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	GenScript ProBio	China	unknown	unknown
38	MTX-COVAB	SARS-CoV-2 S protein	mAb	Preclinical	Memo Therapeutics AG	Switzerland	unknown	unknown
39	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Virna Therapeutics /University of Toronto	Canada	unknown	unknown
40	Anti-SARS-CoV-2 mAbs	SARS-CoV-2 S protein	mAb	Preclinical	Atreca/BeiGene/IGM Biosciences	USA/China	unknown	unknown
41	Anti-SARS-CoV-2 program	SARS-CoV-2	mAb	Preclinical	Xbiotech	USA	Human	unknown
42	MP0420	SARS-CoV-2 S protein	DARPin	Preclinical	Molecular Partners/Novartis	Switzerland/US	unknown	Phage display
43	MP0423	SARS-CoV-2 S protein	DARPin	Preclinical	Molecular Partners/Novartis	Switzerland/US	unknown	Phage display
44	VHH72-Fc	SARS-CoV-2 S protein	single-domain Ab	Preclinical	ExeVir Bio/The University of Texas at Austin/Ghent University/VIB	USA/Belgium	llama	Phage display
45	Nb11-59	SARS-CoV-2 S protein	single-domain Ab	Preclinical	Shanghai Novamab Biopharmaceuticals Co., Ltd	China	camel	Phage display
46	Anti-SARS-CoV-2 VNAR antibodies	SARS-CoV-2 S protein	single-domain Ab	Preclinical	Ossianix	UK	unknown	Phage display
47	Ab8	SARS-CoV-2 S protein	single-domain Ab	Preclinical	University of Pittsburgh School of Medicine/Abound Bio/University of North Carolina/University of Texas Medical Branch/University of British Columbia/University of Saskatchewan	USA	unknown	unknown
48	SI-F019	SARS-CoV-2 S protein	fusion protein	Preclinical	Systimmune	USA	unknown	unknown
49	89C8-ACE2	SARS-CoV-2 S protein	fusion protein	Preclinical	Biotheus Inc.	China	unknown	unknown
50	STI-2020dna	SARS-CoV-2 S protein	mAb (nucleic acid-encoded)	Preclinical	Sorrento Therapeutics	USA	unknown	unknown
51	STI-2020,COVI-AMG	SARS-CoV-2 S protein	mAb	Preclinical	Sorrento Therapeutics	USA	unknown	unknown
52	Ab1+Ab5	SARS-CoV-2 S protein	mAb	Preclinical	Biocytogen/Eucure Biopharma	USA	unknown	unknown
53	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Achilles Vaccines	Italy	unknown	unknown
54	NOVOAB-20	SARS-CoV-2 S protein	mAb	Preclinical	NovoAb Bioanalytics	Canada	unknown	unknown
55	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Y Biologics/Genexine	South Korea	unknown	unknown
56	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Jecho Biopharmaceuticals Co., Ltd., Jecho Labs	China/USA	unknown	unknown
57	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Kaneka Corporation	Japan	unknown	unknown
58	ABP-300 (aka MW05), MW07	SARS-CoV-2 S protein	mAb	Preclinical	Abpro/Mabwell	USA	unknown	unknown
59	DNA-encoded monoclonal antibody	SARS-CoV-2 S protein	mAb (nucleic acid-encoded)	Preclinical	INOVIO/The Wistar Institute/AstraZeneca/the University of Pennsylvania, and Indiana University	USA	unknown	unknown
60	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Eureka Therapeutics	USA	unknown	unknown
61	ACmab1 (COVIMAX)	SARS-CoV-2 S protein	mAb	Preclinical	AXON Neuroscience	CYPRUS	unknown	unknown
62	DNP-019	Undisclosed	mAb	Preclinical	DiNonA, Inc.	South Korea	unknown	unknown
63	AR-711	SARS-CoV-2 S protein	mAb	Preclinical	Aridis Pharmaceuticals, Inc.	USA	unknown	unknown
64	JMB2020	SARS-CoV-2	mAb	Preclinical	Jemincare	China	unknown	unknown
65	Anti-SARS-CoV2 mAb	SARS-CoV-2 S protein	Multi-specific Ab	Preclinical	Ab Studio Inc.	USA	unknown	unknown
66	Anti-SARS-CoV2 mAb	SARS-CoV-2 S protein	mAb	Preclinical	Halberd Corporation / Arizona State University	USA	unknown	unknown
67	Anti-SARS-CoV-2 bispecific mAb	SARS-CoV-2 S protein	mAb	Preclinical	Sorrento Therapeutics	USA	unknown	unknown
68	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Evotec SE	USA	unknown	unknown
69	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Abbvie/Harvard University	USA	unknown	unknown
70	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	MassBiologics/UMass Medical School	USA	unknown	unknown
71	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Icosagen	Estonia	unknown	unknown
72	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Hemogenyx/Immugenyx	USA/UK	unknown	unknown
73	Anti-SARS-CoV-2 mAbs	SARS-CoV-2 S protein	mAb	Discovery	Mount Sinai Health System	USA/China	unknown	unknown
74	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	AbCellera	Canada	unknown	unknown
75	Pan-coronavirus mAb	SARS-CoV-2 S protein	mAb	Discovery	Celltrion	South Korea	unknown	unknown
76	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	YUMAB /Boehringer Ingelheim	Germany	unknown	unknown
77	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Aridis Pharmaceuticals, Inc.	USA	unknown	unknown
78	Anti-SARS-CoV-2 program	SARS-CoV-2 S protein	mAb	Discovery	Amgen and Adaptive Biotechnologies	USA	Human	Single B cell cloning
79	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Chugai/A*STAR	Japan/Singapore	unknown	unknown
80	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Columbia University/Brii Biosciences	USA	unknown	unknown
81	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Coronavirus Immunotherapy Consortium; multiple partners, including Carterra	USA	unknown	unknown
82	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Chelsea and Westminster Hospital, Imperial College London	UK	unknown	unknown
83	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Centivax/ Distributed Bio	USA	Human	unknown
84	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Scripps/IAVI	USA	unknown	unknown
85	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	FairJourney Biologics / Iontas	Portugal	unknown	Phage display
86	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Alliance led by Proteona, including the University Clinic, Heidelberg, Tübingen University Hospital, the German Cancer Research Center (DKFZ), the NMI Natural and Medical Sciences Institute, NUS Enterprise, and 10x Genomics.	Germany/USA	Human	Single B cell cloning
87	Anti-SARS-CoV-2 program	SARS-CoV-2 S protein	mAb	Discovery	International group/Antibody Therapy Against Corona Virus	Sweden/Belgium/Italy/Switzerland	unknown	unknown
88	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Fusion Antibodies, Queen's Univeristy	UK/Canada	unknown	unknown
89	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	BioDuro LLC	USA	unknown	unknown
90	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Hemogenyx Pharmaceuticals plc	UK	Humanized mouse	unknown
91	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Prellis Biologics	USA	unknown	unknown
92	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Eli Lilly/Chugai	USA/Japan	unknown	unknown
93	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Integral Molecular	USA	unknown	unknown
94	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Evotec / Ology Bioservices / DoD	Germany/USA	unknown	unknown
95	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	GC Green Cross	South Korea	unknown	unknown
96	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Formycon AG	Germany	unknown	unknown
97	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	BriaCell Therapeutics Corp.	Canada	unknown	unknown
98	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	AbClon Inc	South Korea	unknown	unknown
99	AV103	SARS-CoV-2 S protein	mAb	Discovery	AbClon Inc	South Korea	unknown	unknown
100	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	University of Amsterdam/Sanquin Research	Netherlands	unknown	unknown
101	IgG1 ab1	SARS-CoV-2 S protein	mAb	Discovery	University of Pittsburgh	USA	unknown	unknown
102	B38, H4, and other mAbs	SARS-CoV-2 S protein	mAb	Discovery	Institute of Microbiology, Chinese Academy of Sciences/Shenzhen Third People’s Hospital/	China	Human	Single B cell cloning
103	4A8	SARS-CoV-2 S protein	mAb	Discovery	Academy of Military Medical Sciences/Westlake University/Tsinghua-Peking Joint Center for Life Sciences	China	Human	Single B cell cloning
104	311mab-31B5, 32D4, and other mAbs	SARS-CoV-2 S protein	mAb	Discovery	Third Military Medical University/Chongqing Public Health Medical Center/Chinese Academy of Medical Sciences and Peking Union Medical College	China	Human	Single B cell cloning
105	414-1 and other mAbs	SARS-CoV-2 S protein	mAb	Discovery	Fudan University/Active Motif	China	Human	Single B cell cloning
106	Anti-SARS mAb	SARS-CoV-2 S protein	mAb	Discovery	Massachusetts Consortium on Pathogen Readiness (MassCPR)	USA	unknown	unknown
107	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Rockefeller University	USA	unknown	unknown
108	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Israel Institute for Biological Research/Dyadic International, Inc.	Israel/USA	unknown	unknown
109	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Virotek/AiVie Inc	USA	unknown	unknown
110	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Affinity Biosciences Pty Ltd	China	unknown	unknown
111	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Tonix Pharmaceuticals Holding Corp.,/Columbia University	USA	unknown	unknown
112	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Pyrizon/Medigus	Israel	unknown	unknown
113	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	Antibody-Drug Conjugate	Discovery	Oncoseek Bio Pvt Ltd,/Oncosimis Biotech Pvt Ltd.,/Reagene Biosciences Pvt Ltd.,/IgY Pvt Ltd.	India/USA	unknown	unknown
114	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Twist Bioscience	USA	unknown	unknown
115	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Ginkgo Bioworks/Totient	USA	unknown	unknown
116	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb (nucleic acid-encoded)	Discovery	Neurimmune AG / Ethris GmbH	Switzerland	unknown	unknown
117	Aeronab 6	SARS-CoV-2 S protein	single-domain Ab	Discovery	University of California, San Francisco	USA	llama	unknown
118	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	single-domain Ab	Discovery	IMMUNOPRECISE ANTIBODIES LTD/Talem Therapeutics, EVQLV	Canada	Llama	Phage
119	rRBD-15	SARS-CoV-2 S protein	single-domain Ab	Discovery	ABLINK Biotech/Chengdu Medical College	China	Synthetic antibody library	Phage display
120	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	single-domain Ab	Discovery	Fudan University	China	Synthetic antibody library	Phage display
121	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	single-domain Ab	Discovery	Chinese Academy of Medical Sciences and Peking Union Medical College	China	Synthetic antibody library	Phage display
122	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	single-domain Ab	Discovery	Beroni Group / Tianjin University	China	unknown	unknown
123	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	single-domain Ab	Discovery	Harvard University	USA	synthetic antibody library	unknown
124	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	single-domain Ab	Discovery	Lumen Bioscience	USA	unknown	unknown
125	Anti-SARS-CoV-2 sdAb	SARS-CoV-2 S protein	single-domain Ab	Discovery	Abcore	USA	unknown	Phage display
126	Anti-SARS-CoV-2 fusion protein	SARS-CoV-2 S protein	fusion protein	Discovery	Cidara Therapeutics, Inc.	USA	unknown	unknown
127	CMAB020, STI-4920, ACE-MAB	SARS-CoV-2 S protein	fusion protein	Discovery	Mabpharm/Sorrento Therapeutics	USA/China	unknown	unknown
128	STI-4398, COVIDTRAP	SARS-CoV-2 S protein	fusion protein	Discovery	Sorrento Therapeutics	USA	unknown	unknown
129	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Columbia University	USA	Human	unknown
130	XAV-19	SARS-CoV-2	polyclonal Abs	Phase 2	Xenothera, LFB/Nantes University Hospital/BPIfrance	France	Swine	unknown
131	SAB-185	SARS-CoV-2 S protein	polyclonal Abs	Phase 1	SAB Biotherapeutics	USA	Transgenic cow	unknown
132	INOSARS	SARS-CoV-2 S protein	polyclonal Abs	Clinical pending	José Fernando Castilleja-Leal, Hospital San Jose Tec de Monterrey	Mexico	Equine	unknown
133	OstriGen SARS-CoV-2 mAbs	SARS-CoV-2 S protein	polyclonal Abs	Preclinical	Ostrich Pharma USA	Japan	Ostrich	unknown
134	IgY-110	SARS-CoV-2 S protein	polyclonal Abs	Preclinical	IGY Life Sciences/MMS Holdings	USA	Avian	unknown
135	GIGA-2050	SARS-CoV-2	polyclonal Abs	Preclinical	GigaGen	USA	Human	unknown
136	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	polyclonal Abs	Preclinical	ThermoGenesis Holdings, Inc., ImmuneCyte	USA	Human	unknown
137	Anti-SARS-CoV-2 mAb	SARS-CoV-2 S protein	mAb	Discovery	Immunome	USA	unknown	unknown
138	Itolizumab (EQ001, H-T1, T1-h)	CD6	mAb	Approved	Biocon	India	unknown	unknown
139	Levilimab (BCD-089)	IL-6R	mAb	Approved	BIOCAD	Russia	unknown	unknown
140	Tocilizumab	IL-6R	mAb	Phase 4	Hoffmann-La Roche/multiple sponsors	USA/Canada/Denmark/Germany/Italy/Netherlands/Spain/UK/Belgium	Mouse	unknown
141	Ravulizumab-cwvz	C5	mAb	Phase 4	Alexion Pharmaceuticals/Cambridge University Hospitals NHS Foundation Trust	USA/UK	Mouse	unknown
142	Sarilumab (SAR153191, Kevzara)	IL-6R	mAb	Phase 4	Regeneron/Sanofi/multiple sponsors	France	Humanized mouse	unknown
143	Siltuximab	IL-6	mAb	Phase 3	University Hospital, Ghent/A.O. Ospedale Papa Giovanni XXIII	USA/Belgium	Mouse	unknown
144	Lenzilumab	GM-CSF	mAb	Phase 3	Humanigen	USA	Human	unknown
145	Canakinumab	IL-1β	mAb	Phase 3	Novartis	USA/France/Germany/Italy/UK/Spain/Russia	unknown	unknown
146	CD24Fc (SACCOVID)	DAMPs, Siglec G/10	fusion protein	Phase 3	OncoImmune	USA	unknown	unknown
147	Olokizumab	IL-6	mAb	Phase 3	R-Pharm JSC/Cromos Pharma	USA	unknown	unknown
148	Leronlimab (PRO-140)	CCR5	mAb	Phase 3	CytoDyn	Canada/USA	Mouse	unknown
149	Emapalumab (Gamifant)	IFN gamma	mAb	Phase 3	Swedish Orphan Biovitrum	Sweden/Italy	Human	unknown
150	Bevacizumab	VEGF	mAb	Phase 3	Qilu Hospital of Shandong University/Renmin Hospital of Wuhan University/Ialy Moriggia Pelascini Gravedona Hospital S.p.A/Wuhan University/Jiangbei Union Hospital of Huazhong University of science and technology/Shandong Provincial Chest Hospital	USA/China	Mouse	unknown
151	IFX-1 (BDB-001)	C5a	mAb	Phase 3	Staidson/InflaRx/Beijing Defengrei Biotechnology	China/Germany/Spain	unknown	unknown
152	Clazakizumab	IL-6	mAb	Phase 3	Medical University of Vienna/NYU Langone Health	Austria/USA	unknown	unknown
153	RPH-104	IL-1	fusion protein	Phase 3	R-Pharm JSC, Cromos Pharma	USA	unknown	unknown
154	Pamrevlumab(FG-3019)	Connective tissue growth factor (aka CCN2)	mAb	Phase 3	FibroGen, Inc.	USA	unknown	unknown
155	Mavrilimumab	GM-CSF receptor	mAb	Phase 3	Kiniksa Pharmaceuticals/multiple sponsors	USA/Italy	Human	Phage display
156	UTTR1147A	IL-22R	fusion protein	Phase 2	Genentech	USA	unknown	unknown
157	F-652	IL-22R	fusion protein	Phase 2	Generon(Shanghai) Corporation Ltd.	China	unknown	unknown
158	APG101	CD95 ligand	fusion protein	Phase 2	Apogenix GmbH	Germany	unknown	unknown
159	Crizanlizumab	P-selectin	mAb	Phase 2	Johns Hopkins University/Novartis/Socar Research SA/Brigham and Women's Hospital	USA	unknown	unknown
160	Garadacimab (CSL312)	Factor XIIa	mAb	Phase 2	CSL Behring	USA	unknown	unknown
161	Infliximab	TNF	mAb	Phase 2	Tufts Medical Center/NIH	USA	unknown	unknown
162	APN01	SARS-CoV-2 S protein	recombinant protein	Phase 2	APEIRON Biologics	Austria/Denmark/Germany	unknown	unknown
163	Otilimab	GM-CSF	mAb	Phase 2	GSK	UK	unknown	unknown
164	Avdoralimab	C5aR	mAb	Phase 2	Innate Pharma SA	France	unknown	unknown
165	Zansecimab (LY3127804)	Ang-2	mAb	Phase 2	Eli Lilly	USA	unknown	unknown
166	Eculizumab	C5	mAb	Phase 2	Alexion Pharmaceuticals/Hudson Medical	USA/France	Mouse	unknown
167	Camrelizumab	PD-1	mAb	Phase 2	Jiangsu HengRui Medicine/Southeast University/Wuhan Jinyintan Hospital	China	Mouse	unknown
168	Pembrolizumab	PD-1	mAb	Phase 2	Medica Scientia Innovation Research (MEDSIR)	Spain	Humanized	unknown
169	Gimsilumab	GM-CSF	mAb	Phase 2	Roivant Sciences	USA	Human	unknown
170	Ixekizumab	IL-17A	mAb	Phase 2	Xiangya Hospital of Central South University	China	Mouse	unknown
171	BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018	IL-8	mAb	Phase 2	Bristol-Myers Squibb	USA	Humanized mouse	unknown
172	Astegolimab	IL-33R	mAb	Phase 2	Genentech	USA	unknown	unknown
173	Secukinumab (AIN457)	IL-17A	mAb	Phase 2	Lomonosov Moscow State University Medical Research and Educational Center	Russia	unknown	unknown
174	ATYR1923	Neuropilin-2	mAb	Phase 2	aTyr Pharma, Inc.	USA	unknown	unknown
175	Axatilimab (SNDX-6352)	CSF-1R	mAb	Phase 2	Syndax Pharmaceuticals, Inc	USA	unknown	unknown
176	NN8765, IPH-2201, NNC141-0100	NKG2A (CD159a)	mAb	Phase 2	Innate Pharma SA	France	unknown	unknown
177	CNTO 136	IL-6	mAb	Phase 2	Janssen	USA	unknown	unknown
178	CERC-002	LIGHT	mAb	Phase 2	Cerecor	USA	unknown	unknown
179	TJM2 (TJ003234)	GM-CSF	mAb	Phase 2	I-MAB	USA/South Korea	unknown	unknown
180	IC14	CD14	mAb	Phase 2	Implicit Bioscience	Australia	unknown	unknown
181	Meplazumab	CD147	mAb	Phase 2	Tang-Du Hospital	China	Mouse	unknown
182	Risankizumab	IL-23 p19	mAb	Phase 2	NIH	USA	unknown	unknown
183	MAS825	TIM-3	mAb	Phase 2	Novartis Pharmaceuticals	USA	unknown	unknown
184	IMP321 (Eftilagimod alpha)	Antigen-presenting cells	fusion protein	Phase 2	Immutep Ltd. (formerly Prima BioMed Ltd)	Austrilia	unknown	unknown
185	ACT017 (Glenzocimab)	Glycoprotein VI platelet	mAb	Phase 2	Acticor Biotech	France	unknown	unknown
186	NGM621	Complement C3	mAb	Phase 2	NGM Bio	USA	unknown	unknown
187	Adrecizumab(HAM8101)	Adrenomedulin	mAb	Phase 1	Adrenomed AG	USA	humanized	unknown
188	CPI-006	CD73	mAb	Phase 1	Corvus Pharmaceuticals	USA	unknown	unknown
189	hzVSFv13	Vimentin	mAb	Phase 1	ImmuneMed	South Korea	unknown	unknown
190	Lanadelumab	kallikrein	mAb	Phase 1	Radboud University/Takeda	USA	unknown	unknown
191	AK119	CD73	mAb	Phase 1	Akesobio	Australia/New Zealand	unknown	unknown
192	Daxdilimab (VBI7734)	ILT7	mAb	Phase 1	Viela Bio	USA	unknown	unknown
193	Efineptakin alfa(GX-17)	IL-7R	recombinant protein	Phase 1	NeoImmuneTech	USA	unknown	unknown
194	Abatacept	CD80/CD86	fusion protein	Clinical pending	BMS	USA	unknown	unknown
195	TAK-671	Proteases	mAb	Clinical pending	Samsung Bioepis Co.,Ltd.,Takeda	South Korea	unknown	unknown
196	Narsoplimab(OMS-721)	MASP-2	mAb	Clinical pending	Omeros Corporation	USA	unknown	unknown
197	Nivolumab	PD-1	mAb	Clinical pending	Centre Leon Berard/Dr Gerry Gin Wai Kwok/Assistance Publique - Hôpitaux de Paris	France/China	unknown	unknown
198	CSL324	G-CSFR	mAb	Clinical pending	CSL Behring	USA	unknown	unknown
199	MEDI3506	IL-33	mAb	Clinical pending	AstraZenaca/UK ACCORD initiative	UL	unknown	unknown
200	Namilumab (IZN-101)	GM-CSF	mAb	Clinical pending	Izana Bioscience/Humanitas Research Hospital	UK/Italy	Human	Phage display
201	Adalimumab	TNF	mAb	Clinical pending	Shanghai Changzheng Hospital/Botnar Research Centre	China/UK	unknown	unknown
202	CMAB806	IL-6R	mAb	Clinical pending	Jinyu Bio-technology Co Ltd	China	unknown	unknown
203	IC100	ASC	mAb	Preclinical	ZyVersa Therapeutics, Inc.	USA	unknown	unknown
204	Anti-IL-1R7 mAb	IL-1R7	mAb	Preclinical	IcanoMAB	Germany	unknown	unknown
205	NI-0101	TLR4	mAb	Preclinical	Edesa Biotech/Light Chain Bioscience	USA/Switzerland	unknown	unknown
206	NI-0801	CXCL10	mAb	Preclinical	Edesa Biotech/Light Chain Bioscience	USA/Switzerland	unknown	unknown
207	Pritumumab	Vimentin	mAb	Preclinical	Nascent Biotech	USA	Human	unknown
208	Neutralizing antibody	4-1bb	mAb	Preclinical	Eutilex	South Korea	unknown	unknown
209	TZLS-501 (NI-1201)	IL-6R	mAb	Preclinical	Tiziana Life Sciences/NovImmune	USA	Human	unknown
210	REGN3048-3051	MERS-CoV	mAb	Preclinical	Regeneron Pharmaceuticals	USA	Humanized mouse or Human	unknown
211	ALT-100	NAMPT	mAb	Preclinical	Aqualung Therapeutics / Fusion Antibodies	USA	unknown	unknown
212	Anti-SARS-CoV-2 program	SARS-CoV-2, NKp46	Multi-specific Ab	Preclinical	Cytovia Therapeutics, Inc.	USA	unknown	unknown
213	radiotherapeutics (uPRITs)	Plasminogen Activator Receptor (uPAR)	radiotherapeutics (uPRITs)	Preclinical	Monopar/NorthStar	USA	unknown	unknown
214	Foralumab	CD3	mAb	Preclinical	Tiziana Life Sciences plc	UK	unknown	unknown
215	Undisclosed	Undisclosed	fusion protein	Discovery	JN Nova Pharma	Canada	unknown	unknown
216	KSI-501	VEGF/IL-6	Multi-specific Ab	Discovery	Kodial Sciences Inc.	USA	unknown	unknown
217	TriKE anti-SARS-CoV-2	CD16/SARS-CoV-2	Multi-specific Ab	Discovery	GT Biopharma, Inc.	USA	unknown	unknown

Dec 2020: Three clinical trials are ongoing: NCT04425629 (phase 2/3), NCT04426695 (phase 1/2), phase (3).

Nov 21,2020: Regeneron Pharmaceuticals today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Casirivimab and imdevimab administered together are authorized for the treatment of mild to moderate COVID-19 in adults, as well as in pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization. The clinical evidence from Regeneron's outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Oct 28,2020: Regeneron announced that its new crown neutralizing antibody cocktail therapy REGN-COV2 has reached the primary and critical secondary endpoints in an ongoing Phase 2/3 clinical trial. REGN-COV2 significantly reduces the patient's viral load and the need for further medical care (including hospitalization, emergency room visits, emergency care and/or doctor's office/telemedicine visits).Sep 14, 2020: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the University of Oxford today announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world's largest randomized clinical trials of potential COVID-19 treatments, will evaluate Regeneron's investigational anti-viral antibody cocktail, REGN-COV2. The Phase 3 open-label trial in patients hospitalized with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.

REGN-COV2 is the first specifically designed COVID-19 therapy being evaluated by RECOVERY. It was selected in part based on its emerging safety profile in humans, pre-clinical data showing it could protect against viral escape mutations, and prevention and treatment studies in non-human primates showing it reduced the amount of virus and associated damage in the lungs. REGN-COV2 is currently being studied in two Phase 2/3 clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals.

July 6, 2020: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial (NCT04452318) will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). REGN-COV2 has also moved into the Phase 2/3 portion of two adaptive Phase 1/2/3 trials testing the cocktail's ability to treat hospitalized and non-hospitalized (or "ambulatory") patients with COVID-19.

June 15, 2020: Regeneron preported their antibody discovery and preclinical data as two papers on Science.

June 11,2020: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initiation of the first clinical trials of REGN-COV2 (NCT04425629, NCT04426695), its investigational dual antibody cocktail for the prevention and treatment of COVID-19.

The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure (such as healthcare workers or first responders) and uninfected people with close exposure to a COVID-19 patient (such as the patient's housemate). The placebo-controlled trials will be conducted at multiple sites.

Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's proprietary VelocImmune® mice, as well as antibodies isolated from humans who have recovered from COVID-19. They selected the two most potent, non-competing and virus-neutralizing antibodies and have scaled them up for clinical use with the company's in-house VelociMab® and manufacturing capabilities. The two antibodies bind non-competitively to the critical receptor binding domain (RBD) of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment, as demonstrated in upcoming Science publications of preclinical research.

The first two adaptive Phase 1/2/3 studies are evaluating REGN-COV2 (REGN10933+REGN10987) as a treatment for hospitalized and non-hospitalized patients with COVID-19. The Phase 1 portion will focus on virologic and safety endpoints, and the Phase 2 portion will focus on virologic and clinical endpoints. Data from the Phase 1 and Phase 2 studies will be used to refine the endpoints and determine size for the Phase 3 studies.

Nov 20,2020: Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization, Eli Lilly and Company (NYSE: LLY) announced. This authorization, the second authorization around the world for bamlanivimab, is based on data from BLAZE-1, a randomized, double-blind placebo-controlled phase 2 study in patients with recently diagnosed, mild to moderate COVID-19.

Nov 9,2020: the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.

Oct 26,2020: Based on an updated dataset from the trial, no additional COVID-19 patients in this hospitalized setting will receive bamlanivimab. This recommendation was based on trial data suggesting that bamlanivimab is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease. In this updated dataset, differences in safety outcomes between the groups were not significant.

Oct 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

For monotherapy, Lilly is focused on the 700 mg dose of LY-CoV555 since similar clinical effects were seen across all dose levels tested in BLAZE-1. Lilly anticipates it could supply as many as one million doses of 700 mg LY-CoV555 monotherapy in Q4 2020, with 100,000 available in October. With respect to the supply of combination therapy, Lilly anticipates it will have 50,000 doses available in Q4 2020. The supply of combination therapy will increase substantially beginning in Q1 2021, as additional manufacturing resources come online throughout the year, including Lilly's recently announced manufacturing collaboration with Amgen (NASDAQ: AMGN). Lilly is also pursuing additional partnerships to provide antibodies to resource-limited countries.

Based on the combination therapy data, along with the previously disclosed findings for LY-CoV555 monotherapy, Lilly has engaged global regulators, including the FDA regarding potential EUA. Lilly has now submitted an initial request for EUA for LY-CoV555 monotherapy in higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19. We expect to submit a subsequent request for EUA for combination therapy in November, pending clinical trial enrollment, once additional safety data accumulate and sufficient supply is manufactured. Lilly anticipates having data to support a biologics license application (BLA) submission for combination therapy as early as Q2 2021.

Sep 16 2020: Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a SARS-CoV-2 neutralizing antibody, for the treatment of symptomatic COVID-19 in the outpatient setting. The trial enrolled mild-to-moderate recently diagnosed COVID-19 patients across four groups (placebo, 700 mg, 2800 mg, and 7000 mg).

The prespecified primary endpoint, change from baseline in viral load at day 11, was met at the 2800 mg dose level, but not the others. Most patients, including those receiving placebo, demonstrated near complete viral clearance by day 11. Additional analyses of viral data demonstrated that LY-CoV555 improved viral clearance at an earlier time point (day 3) and reduced the proportion of patients with persistently high viral load at later time points.

Aug. 3, 2020: Eli Lilly and Company (NYSE: LLY) today announced the initiation of BLAZE-2, a Phase 3 trial (NCT04497987) studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities). LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera, is a neutralizing antibody against SARS-CoV-2, the virus that causes COVID-19.

AbCellera has identified over 500 unique fully human antibody sequences from one of the first U.S. patients who recovered from COVID-19. Other clincials trials: NCT04427501, NCT04501978, NCT04518410, NCT04411628

Dec 17, 2020: Two randomized, controlled Phase 3 clinical trials have begun evaluating investigational monoclonal antibodies for their safety and efficacy in treating people hospitalized with moderate COVID-19. The trials are part of the ACTIV-3 master protocol, which has an adaptive design allowing investigators to add new sub-studies of additional investigational agents. ACTIV-3 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. One sub-study is evaluating VIR-7831, a monoclonal antibody developed through a partnership between GlaxoSmithKline plc (Brentford, United Kingdom) and Vir Biotechnology, Inc. (San Francisco). The other sub-study is evaluating the combination of BRII-196 and BRII-198, two neutralizing monoclonal antibodies manufactured by Brii Biosciences (Durham, North Carolina and Beijing). Antibodies are infection-fighting proteins naturally made by the immune system. Antibodies can prevent viruses from infecting cells, sometimes by binding to the surface of the viruses. Synthetic versions of these antibodies, prepared in a laboratory, are known as monoclonal antibodies.

Oct 6 2020: Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2 lead-in

Initial Phase 3 results may be available as early as the end of 2020; results for the primary endpoint are expected in the first quarter of 2021, with current estimates at January 2021

Sep 1, 2020:Vir and GSK announced that the first patient was dosed last week in a phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalisation.

VIR-7831 and VIR-7832 are monoclonal antibodies that have demonstrated the ability to neutralize SARS-CoV-2 live virus. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved. VIR-7831 and VIR-7832 are based on the S309 antibody. Planned Phase 2 trial in three to five months (July to September, 2020).

On June 9, Vir Biotechnology discloses that it inked a collaboration agreement with GlaxoSmithKline aimed at developing and commercializing products for the prevention, treatment and prophylaxis of SARS-CoV-2-related diseases. The partnership will focus on three principal programs: antibodies targeting the virus, vaccines and products based on CRISPR screening of host targets expressed in connection to exposure to SARS-CoV-2. All three include the possibility of including other coronaviruses. For the next four years, the companies will conduct R&D activities under mutually agreed plans and budgets for each of the three programs.

May 29, 2020 Vir Biotechnology, Inc. announced that is has finalized a process development and manufacturing agreement with Biogen Inc. 4. Apr 14, 2020 Vir announces that it will work with Samsung Biologics for large-scale production.

Mar 29, 2020 Xencor, Inc. announced it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19. https://investors.xencor.com/news-releases/news-release-details/xencor-and-vir-biotechnology-enter-license-agreement-use-xtendtm.

April 6, 2020, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. During the agreement period, generally, subject to certain rights granted to WuXi Biologics (Hong Kong) Limited (“WuXi”) under existing agreements between WuXi and VIR, the parties will have an exclusive research collaboration with respect to antibody products directed to SARS-CoV-2 or to any other coronavirus. https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions.

July 30, 2020: Celltrion Group announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the company’s Clinical Trial Authorisation (CTA) application for a Phase I clinical trial with CT-P59, a COVID-19 antiviral antibody treatment candidate, in patients with mild symptoms of SARS-CoV-2 infection. The clinical trial is set to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59. Celltrion plans to conduct further global Phase II/III trials in patients with mild and moderate COVID-19 and anticipates results from these pivotal studies by the end of the year. Furthermore, a clinical trial investigating the use of CT-P59 as a preventative measure, by enrolling people in close contact with COVID-19 patients globally, is also planned and the topline data for this trial are anticipated in Q1 of 2021. Celltrion will start the full-scale commercial production of CT-P59 in September this year and is securing sufficient manufacturing capacity to produce enough of the potential COVID-19 treatment for up to 5 million patients a year.

July 17,2020: Celltrion Group today announced the launch of its Phase I human clinical trial investigating a potential antiviral antibody treatment for patients with COVID-19. The in-human study follows positive pre-clinical results for the treatment candidate and subsequent approval of the Investigational New Drug application by the Korean Ministry of Food and Drug Safety (MFDS). The potential treatment will also be investigated for use as a preventative measure.The Phase I clinical trial aims to enroll 32 healthy volunteers in collaboration with Chungnam National University Hospital. The study will evaluate the safety of the antiviral antibody treatment candidate in healthy participants who have not been diagnosed with COVID-19. The trial’s completion is expected by Q3 of this year.

Celltrion has identified the library of antibodies sourced from the blood of recovered patients in Korea, which are thought to be involved in neutralising the virus and may contribute to recovery from COVID-19. Plan to start human trial in July, 2020. On APRIL 13 2020, Celltrion announced that the company has successfully selected the most potent antibody candidates to neutralize SARS-CoV-2, the virus causing COVID-19. Through a partnership with the Korea Centers for Disease Control and Prevention (KCDC), Celltrion initially identified and secured 300 different types of antibodies that bind to the SARS-CoV-2 antigen. These were then screened based on their ability to bind to the virus spike protein. Celltrion was then able to capture a total of 38 potent neutralizing antibodies, of which, 14 are powerful neutralizing antibodies against SARS-CoV-2. Following the selection of antibody candidates which demonstrate high potency in neutralizing SARS-CoV-2, Celltrion will begin cell-line development. Once this is completed, Celltrion aims to roll out mass production of the therapeutic antibody and, together with the KCDC, Celltrion will conduct efficacy and toxicity testing in mice and non-human primates.

Sep 16,2020: Registed for Phase II study(NCT04551898).

September 3 2020: last update posted: The primary purpose of this Phase 1 study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants. The estimated primary completion date is October 15, 2020.

August 27: BeiGene snagged exclusive rights to develop and commercialize Singlomics Biopharmaceuticals’ Covid-19 antibodies outside of Greater China, thus expanding the company’s search for a potential treatment. Under the license agreement, BeiGene can develop, manufacture and commercialize Singlomics’ DXP-593 and DXP-604 in “ex-China territory.” The Beijing-based biotech is set to begin a Phase I study in Australia next month, enrolling up to 30 healthy volunteers. A second multinational Phase I/II study is expected to begin by early October in patients with mild to moderate Covid-19.

A joint research team from Beijing Advanced Innovation Center for Genomics (ICG) at Peking University (PKU) has successfully identified multiple highly potent neutralizing antibodies against the novel coronavirus SARS-CoV-2, the causative virus of the respiratory disease COVID-19, from convalescent plasma by high-throughput single-cell sequencing. Published on Cell, the team reported rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1+ clonotypes, 14 potent neutralizing antibodies were identified with the most potent one, BD-368-2, exhibiting an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8Å Cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody’s epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2 neutralizing antibodies could be directly selected based on similarities of their predicted CDR3H structures to those of SARS-CoV neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases.

Sep 18,2020: SRNE announced that it has received a clearance from the FDA to begin the phase I study on its proprietary antibody candidate STI-1499 (COVI-GUARD) for the treatment of hospitalized COVID-19 patients.

Per the company, this study will enroll patients rapidly, which will lay out a path for a larger study, data from which can be used for potential Emergency Use Authorization (EUA) filing before the end of this year. Sorrento already started cGMP manufacturing to deliver 50,000 doses of STI-1499 in anticipation of a potential EUA, if approved.

Notably, STI-1499 demonstrated 100% in vitro neutralizing effect against SARS-CoV-2 while preventing infection of healthy cells in pre-clinical in-vitro studies. Moreover, the antibody developed by the candidate has been 100% effective against the highly contagious strain of SARS-CoV-2, namely the D614G variant, in preclinical studies.

July 1, 2020: Sorrento Therapeutics initiated a phase I clinical trial (NCT04454398) to Evaluate STI-1499 (COVI-GUARD) in Hospitalized Patients With COVID-19.

June 5, 2020：SAN DIEGO, June 5, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has completed a preclinical batch of the STI-4398 (COVIDTRAP) protein and is reporting the positive results from preclinical testing of its ability to neutralize and inhibit SARS-CoV-2 virus from infecting ACE2-expressing cells, VERO/E6.

May 8, 2020, Sorrento Therapeutics, Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD™) to potentially treat COVID-19. Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai and his team screened approximately fifteen thousand individuals who may have had and recovered from COVID-19 for the presence of anti-COVID-19 antibodies. The screening used a diagnostic test developed by Florian Krammer, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, and authorized for use in Mount Sinai's laboratory under an FDA Emergency Use Authorization. Sorrento will have access to plasma containing antibodies against COVID-19 for the purpose of identification and production of monoclonal antibodies with potential neutralizing activity against SARS-CoV-2.Sorrento is completing all IND filing requirements for the triple antibody combination therapy and expects to commence phase 1 trials of the drug candidate in the third quarter of 2020.

Oct 19,2020: The Phase 1 study (NCT04590430) is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants. Blood tests will be done to check how much HFB30132A is in the bloodstream and how long the body takes to eliminate it. Participation may include up to ten visits to the study center.

Sep 14,2020: HiFiBiO started cooperation with ABL Bio for developing CoV-2 neutralizing antibody HFB30132A.

August 17, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, today announced a collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance headquartered at the La Jolla Institute for Immunology (LJI). CoVIC was established to accelerate discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2. It has received support from the COVID-19 Therapeutics Accelerator, which was launched in March 2020 by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard with additional funding from a range of donors.

Using a combination of its proteomics and proprietary single-cell profiling technology, HiFiBiO has developed multiple SARS-CoV-2 neutralizing antibodies with the potential for both therapeutic and prophylactic applications. With an aligned commitment to deliver accessible therapies to vulnerable individuals globally, the company has submitted 10 distinct antibodies in the format of mono- or bispecific antibodies to CoVIC for in vitro and in vivo testing. HiFiBiO will gain a first look into the performance of its antibodies compared to dozens of other submitted antibodies and synergies among them for combinational therapies.

Additionally, HiFiBiO Therapeutics is preparing an Investigational New Drug (IND) application with the US Food and Drug Administration for HFB30132A, a novel SARS-CoV-2 neutralizing antibody for the treatment of COVID-19 patients. The highly differentiated antibody has been rapidly identified, engineered, and evaluated in all key preclinical studies, where it has demonstrated outstanding efficacy, exposure, and safety profile. A planned Phase I single-IV administration ascending dose study will assess the safety and tolerability of HFB30132A in healthy volunteers later this summer.

VIR-7832 is monoclonal antibodies that have demonstrated the ability to neutralize SARS-CoV-2 live virus. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved. VIR-7831 and VIR-7832 are based on the S309 antibody. Planned Phase 2 trial in three to five months (July to September, 2020).

On June 9, Vir Biotechnology discloses that it linked a collaboration agreement with GlaxoSmithKline aimed at developing and commercializing products for the prevention, treatment and prophylaxis of SARS-CoV-2-related diseases. The partnership will focus on three principal programs: antibodies targeting the virus, vaccines and products based on CRISPR screening of host targets expressed in connection to exposure to SARS-CoV-2. All three include the possibility of including other coronaviruses. For the next four years, the companies will conduct R&D activities under mutually agreed plans and budgets for each of the three programs.

May 29, 2020 Vir Biotechnology, Inc. announced that is has finalized a process development and manufacturing agreement with Biogen Inc. 4. Apr 14, 2020 Vir announces that it will work with Samsung Biologics for large-scale production.

Mar 29, 2020 Xencor, Inc. announced it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19. https://investors.xencor.com/news-releases/news-release-details/xencor-and-vir-biotechnology-enter-license-agreement-use-xtendtm.

April 6, 2020, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. During the agreement period, generally, subject to certain rights granted to WuXi Biologics (Hong Kong) Limited (“WuXi”) under existing agreements between WuXi and VIR, the parties will have an exclusive research collaboration with respect to antibody products directed to SARS-CoV-2 or to any other coronavirus. https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions.

RANCHO CORDOVA, Calif., June 8, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, the research partner of ThermoGenesis' joint venture, ImmuneCyte, Inc., published the results of ImmuneCyte's licensed, fully human neutralizing antibody therapeutics for COVID-19 in an article entitled, "Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries," in bioRxiv on June 6, 2020. ThermoGenesis Holdings, Inc. 's joint venture partner, ImmuneCyte, has acquired from its collaborators worldwide intellectual property of four high-affinity monoclonal antibody drug candidates against COVID-19 virus. These high-affinity neutralizing monoclonal antibodies were obtained from the screening of enriched B cell libraries from individuals who have recently recovered from COVID-19 (i.e. from convalescent whole blood). The technologies were originally developed by a research team affiliated with East China Normal University, one of the most prestigious universities in China. The acquisition includes an undisclosed upfront cash payment and low double-digit future revenue sharing for the monoclonal antibody drug candidates under development. ThermoGenesis currently holds approximately 19% of the equity of ImmuneCyte.

In the paper disclosed on Biorxiv : The team describe the generation of antibody libraries from 17 different COVID-19 recovered patients and screening of neutralizing antibodies to SARS-CoV-2. After 3 rounds of panning, 456 positive phage clones were obtained with high affinity to RBD (receptor binding domain). Then the positive clones were sequenced and reconstituted into whole human IgG for epitope binning assays. After that, all 19 IgG were classified into 6 different epitope groups or Bins. Although all these antibodies were shown to have ability to bind RBD, the antibodies in Bin2 have more superiority to inhibit the interaction between spike protein and angiotensin converting enzyme 2 receptor (ACE2). Most importantly, the antibodies from Bin2 can also strongly bind with mutant RBDs (W463R, R408I, N354D, V367F and N354D/D364Y) derived from SARS-CoV-2 strain with increased infectivity, suggesting the great potential of these antibodies in preventing infection of SARS-CoV-2 and its mutations. Furthermore, these neutralizing antibodies strongly restrict the binding of RBD to hACE2 overexpressed 293T cells. Consistently, these antibodies effectively neutralized pseudovirus entry into hACE2 overexpressed 293T cells. In Vero-E6 cells, these antibodies can even block the entry of live SARS-CoV-2 into cells at only 12.5 nM. These results suggest that these neutralizing human antibodies from the patient-derived antibody libraries have the potential to become therapeutic agents against SARS-CoV-2 and its mutants in this global pandemic.

Sep. 2, 2020-- Twist Bioscience Corporation (Nasdaq: TWST) today announced data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies, both Immunoglobulin G (IgG) antibodies and substantially smaller single domain VHH “nanobodies,” against SARS-CoV-2, the virus that causes COVID-19. These neutralizing effects were found to be comparable to or better than those seen with antibody candidates derived from patients who had recovered from COVID-19. The data were collected from studies conducted by Saint Louis University and independently verified by scientists at Colorado State University. The results from both the IgG and VHH antibodies generated by Twist Biopharma warrant advancement of several of these compounds into animal studies and potentially into human clinical trials.

June 9, 2020 I Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Serimmune Inc., a leader in understanding the functional antibody repertoire's role in human disease, today announced a collaboration to identify and evaluate SARS-CoV-2 therapeutic antibody candidates from Twist libraries.

The collaboration will evaluate existing Twist antibody candidates that bind with high affinity to either SARS-CoV-2 S1 spike protein or the human ACE2 cellular receptor, using Serimmune's Serum Epitope Repertoire Analysis (SERA) platform, which maps the antigenic targets of antibody repertoires. Epitopes identified in the first phase will then be used to re-screen Twist's proprietary synthetic antibody discovery libraries to identify and evaluate new candidates while at the same time further increasing the specificity of antibody candidates. Twist will be responsible for advancing all antibodies resulting from the collaboration.

"Beginning with our first efforts in January, Serimmune has focused on understanding the role of antibody response in SARS-CoV-2 infection. Having evaluated a diverse set of samples from subjects with diverse symptoms, we are beginning to more fully understand the immunogenic epitopes associated with natural infection," said Noah Nasser, CEO of Serimmune. "Twist's fully human antibody libraries contain a vast and diverse collection of potential therapeutic candidates, and we look forward to providing valuable SARS-CoV-2 epitope information to help them select and advance the most promising candidates to treat this devastating disease."

"We are working feverishly to move our antibody leads through characterization, while at the same time implementing the best tools to optimize the properties of each antibody," said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Serimmune's platform will allow us to accelerate our efforts in a targeted and methodical manner to further increase the specificity of our antibodies, continuing our sprint in delivering new therapeutics to treat COVID-19."

March 24, 2020. Sorrento Therapeutics, Inc. announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited, for the clinical development and commercialization of the ACE-MAB fusion protein (Sorrento’s product code name STI-4920 and Mabpharm’s product code name CMAB020) for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. Mabpharm has generated a fusion protein (CMAB020) that binds to the spike protein of the SARS-CoV-2 virus.March 31, 2020 Sorrento Therapeutics, Inc.announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. Sorrento is currently conducting preclinical development of multiple therapeutic candidates to treat COVID-19 across its proprietary platforms, including natural killer (NK) cell therapies, neutralizing antibodies (NAbs) and soluble recombinant fusion protein traps (COVIDTRAPTM) to potentially inhibit the binding of SARS-CoV-2’s spike protein with host ACE2 receptors, thereby potentially preventing viral cell entry. ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory epithelial cells or ACE2-expressing cells to interrupt the viral life cycle -- ACE-MAB is in the cGMP cell line development stage by our strategic partner, Mabpharm Limited, and could be ready for large-scale production in Mabpharm’s 30,000 m2 cGMP facilities in China for human clinical trials and commercialization upon receipt of requisite regulatory approvals -- Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets. Designed as a bi-specific fusion protein, ACE-MAB has two functional arms. One arm (Ab) is a fully human antibody that targets the spike protein of SARS-CoV-2 with high affinity. The other arm (TR) is a truncated ACE2 protein that binds to a different epitope of the spike protein. The ACE-MAB fusion protein could also block the receptor binding domain (RBD) with CD147 to mitigate lung inflammation and cytokine storm. The dual-arm design could be a unique advancement, potentially providing binding to the SARS-CoV-2 virus that is sufficient to prevent the virus from invading normal human cells. ACE-MAB retains the ACE2 enzymatic function, which could provide benefits such as reduced vasoconstriction and increased blood flow to infected lung tissue. The ACE2 arm competes with RBD binding to respiratory epithelial or other cells. It should preserve the ACE2 enzymatic activity, which is important in maintaining normal blood pressure and healthy blood flow into patients with infected lung tissue, which would include patients with advanced COVID-19 disease.

MARCH 31, 2020: Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodies demonstrate a strong ability to neutralize SARS-CoV-2 viruses. Dr. Tsukamoto said: "We have produced ostrich antibodies to many viruses, bacteria, and allergens, but we were pleased to see how quickly the ostriches developed immunity and placed the anti-SARS-CoV-2 antibodies in their eggs. We were even more pleased to see how capable the antibodies were in blocking the virus that causes COVID-19."Ten ostriches have been vaccinated, and the antibodies from their eggs have already been used in masks, nasal drops, and candies in Japan. Masks with antibody-impregnated liners have been proven to block 99.9% of influenza viruses. More than 70 medical institutions in Japan have purchased large numbers of ostrich antibody masks to prevent infections among healthcare workers, and the order rate is increasing. The Rinku Medical Clinic, a cancer hospital in Osaka, Japan, has begun a clinical trial on the use of ostrich antibody nasal drops to prevent hospital-acquired coronavirus infection. If a patient infected with SARS-CoV-2 is present, a doctor will spray the antibody solution into the nasal cavity of hospitalized patients, close contacts, and healthcare professionals. According to Dr. Takahiro Ishikawa, President of the Rinku Medical Clinic, "In the absence of vaccines and therapeutics, proving that the ostrich antibody nasal drops have a preventive effect could be a real breakthrough."Dr. Tsukamoto’s research also encompasses the study of the ostrich antibodies as a therapeutic. He and his research team have published results showing one hundred per cent efficacy of H5N1 (avian influenza) antibodies injected into chickens infected with the avian influenza virus. To reduce potential rejection after inoculation into humans, Dr. Tsukamoto is developing an antibody drug that uses various enzymes to cut ostrich antibody molecules into smaller molecules containing antigen-binding regions.According to Ostrich Pharma USA Co-CEO Stuart Greenberg, "We recognize the enormous need for multiple approaches to the COVID-19 pandemic in the US. In order to be a participant in this war, we will need to immunize large numbers of ostriches, purify large amounts of the antibodies from the ostrich eggs, and get manufacturing capacity to make products, like masks. We will need to develop an approach to marketing, including defining the regulatory path, when appropriate. We expect to team with some key partners to accomplish this."Ostrich Pharma USA, under the trade name “OstriGen,” is exploiting the powerful immune system of the ostrich to develop a revolutionary class of treatments and prophylaxes that are highly effective and economical.

As listed on clinicaltrials.gov on September 7, 2020, five clinical trials are currently registerd: four are recruiting(NCT04447469 NCT04463004, CT04492514, NCT04399980), one is not recruiting yet (NCT04397497).

April 29, 2020: Kiniksa recently announced evidence of treatment response with mavrilimumab from an open-label treatment protocol in 6 non-mechanically ventilated patients with severe COVID-19 pneumonia and hyperinflammation in Italy. All 6 of these patients showed an early resolution of fever and improvement in oxygenation within 1-3 days, none of the patients progressed to require mechanical ventilation, and 3 of the patients were discharged from the hospital within 5 days. Mavrilimumab was well-tolerated. An additional 7 non-mechanically ventilated patients with COVID-19 pneumonia and hyperinflammation have since been treated with mavrilimumab. The results from these patients are consistent with the first 6 patients treated. One of the 7 patients was electively intubated and subsequently returned to low-level supplemental oxygen. All 13 patients improved clinically, and 12 out of 13 patients returned home. Kiniksa has engaged with the U.S. Food and Drug Administration (FDA) and is preparing for a potential registrational development program for mavrilimumab in COVID-19 pneumonia and hyperinflammation. In parallel, academic investigators in the U.S. and Italy are planning investigator-initiated placebo-controlled studies. March 31, 2020, Kiniksa Pharmaceuticals announced early evidence of treatment response with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in a treatment protocol in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation. The treatment protocol was conducted by Professor Lorenzo Dagna, MD, FACP, Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy within a COVID-19 Program directed by Professor Alberto Zangrillo, Head of Department of Anesthesia and Intensive Care of the Scientific Institute San Raffaele Hospital and Professor in Anesthesiology and Intensive Care, Università Vita-Salute San Raffaele. Reference to utility of blocking GM-CSF: Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. Pre-Print. 2020.

Data Landscape

Refinement Search

This section is provided to help you refine search and quickly navigate to the references to the antibodies.

COVID-19 Antibody Therapeutics Tracker

Legacy Manually Cleaned

About this dataset

References

Stats at a Glance

217

62

2

203

Data Table

Data Landscape

Refinement Search

Target

Status

Format

Country